Skip to main content

Merck tops earnings expectations, thanks to strong cancer-drug sales

Pharmaceutical giant Merck & Co. Inc. blew away earnings expectations in the second quarter, thanks to soaring sales of its blockbuster cancer drug Keytruda.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.